| CARVIEW |
Select Language
HTTP/2 200
date: Tue, 30 Dec 2025 11:50:08 GMT
content-type: text/html
server: cloudflare
cf-ray: 9b61515ea9430cfe-BOM
cf-cache-status: HIT
age: 404767
content-encoding: gzip
last-modified: Thu, 25 Dec 2025 19:24:01 GMT
strict-transport-security: max-age=31536000
content-security-policy: frame-ancestors 'self'
surrogate-control: max-age=432000
surrogate-key: www.macuject.com 5f55a0777751f584a3bc2840 pageId:5f55a0777751f5868ebc2842 5f55a0777751f578d0bc2875
x-frame-options: SAMEORIGIN
x-lambda-id: bfc4c393-2392-480e-b5bc-26206e82956f
vary: accept-encoding
set-cookie: _cfuvid=Xxt3edDfDTrK5vPmfDhQMQzRmAoEakLF1WiraYdclfU-1767095408776-0.0.1.1-604800000; path=/; domain=.www.macuject.com; HttpOnly; Secure; SameSite=None
alt-svc: h3=":443"; ma=86400
Macuject
.svg)
.jpeg)
Clinical decision support software for
Learn more how we help people.png)
Request a demo.jpg)
.png)
Request a Demo
More News
Decisions with Vision
Clinical decision support software for
macular disease
Learn more how we help peopleThe Problem
Age-Related Macular Degeneration (AMD) is a loss of vision caused by fluid build-up in the retina. It is the most common causes of blindness in developed countries, affecting 10% of people over 60.
There are currently more than 180 million people suffering from AMD worldwide, with in excess of 25 million suffering from wet (neovascular) AMD in which fluid leaks into the macula.
Highly effective treatment exists, but most AMD sufferers do not receive optimal treatment, even in wealthy countries.
Macuject addresses this shortfall by assisting doctors to see more patients and reach the best treatment decisions more efficiently.
More About AMDThere are currently more than 180 million people suffering from AMD worldwide, with in excess of 25 million suffering from wet (neovascular) AMD in which fluid leaks into the macula.
Highly effective treatment exists, but most AMD sufferers do not receive optimal treatment, even in wealthy countries.
Macuject addresses this shortfall by assisting doctors to see more patients and reach the best treatment decisions more efficiently.
The Macuject Platform
Macuject is a cloud-based software platform with 3 parts:
Analysis
Proprietary AI analysis measures fluid in the macula
Dashboard
Review dashboard presents the entire patient history at a glance
Decision tree
Clinical decision tree helps doctors reach their best decisions faster and more reliably
The Workflow
AMD patients progress through up to 5 stages during the Macuject workflow
Retinal Scan
OCT scans of both eyes
Image Analysis
256 images are processed to measure macular fluid volumes for every clinic visit
Review Dashboard
Review the entire history of fluid volumes, visual acuities and treatment protocols at a glance
Decision Tree
Optimised process guided by fluid findings and clinician preferences
Treatment
Deliver the selected regimen,
ongoing mangagement
ongoing mangagement
Benefits for Doctors
Macuject has multiple benefits for clinicians treating wet AMD.
Read more hereClinical Confidence
Reach your decisions faster and more reliably
Ease of Use
Workflow improvement - image analysis, history dashboard and decision tree all on one screen
Data for Audits
Personal benchmarking and clinical audit for clinicians & CPD
Data Insights
Macuject provides valuable insights into optimal treatments for wet AMD.
Read more hereFor Doctors
Highlight effective patterns of treatment and potential improvement in outcomes
For Pharma
Link real-world treatment preferences and decisions to drugs and patient outcomes
For Payors
Identify protocols that consistently deliver the best real-world results
Latest News
2024. All rights reserved
News
News Articles